[go: up one dir, main page]

JPS6261313B2 - - Google Patents

Info

Publication number
JPS6261313B2
JPS6261313B2 JP53144400A JP14440078A JPS6261313B2 JP S6261313 B2 JPS6261313 B2 JP S6261313B2 JP 53144400 A JP53144400 A JP 53144400A JP 14440078 A JP14440078 A JP 14440078A JP S6261313 B2 JPS6261313 B2 JP S6261313B2
Authority
JP
Japan
Prior art keywords
lysozyme
solution
add
aqueous solution
hydrochloric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP53144400A
Other languages
Japanese (ja)
Other versions
JPS5571490A (en
Inventor
Kazumi Ogata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Priority to JP14440078A priority Critical patent/JPS5571490A/en
Publication of JPS5571490A publication Critical patent/JPS5571490A/en
Publication of JPS6261313B2 publication Critical patent/JPS6261313B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Enzymes And Modification Thereof (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は安定なリゾチーム水溶液の製造法に関
する。 リゾチームはフレミングによつて1922年に発見
されたアミノ酸129個からなる塩基性蛋白質で、
人の体液を含め広く天然物中に分布し、ムコ多糖
類を加水分解する酵素である。またそれは抗炎
症、止血、抗ウイルス、抗結膜炎その他の抗眼炎
症等の薬理作用を示し、医薬品としても重要であ
る。 しかし、公知の方法で得たリゾチーム、または
リゾチーム酸塩を用いて作つたリゾチームの酸性
水溶液を長時間放置すると沈澱または浮遊物を生
じる。また、リゾチームは塩化リゾチームの形態
で市販されており、その水溶液はPH3.0−3.6を示
し一応安定とされている。しかしながら、市販の
リゾチームの結晶には、アルブミン系の不純物ま
たは変性したリゾチームが含有されているため水
溶液のPHが3.0〜3.6であつても長期に保存して置
くと沈澱物または浮遊物となつて析出する。 本発明者はこのような欠点のない長期保存に耐
えるリゾチーム水溶液の製造について研究を重ね
た結果、意外にも極めて簡単な処理、すなわちリ
ゾチーム水溶液をPH5.0〜11.0の間で、必要に応
じてパルプを加え軽く撹拌して、析出する微量の
不純物を濾去した後、酸を加えてPH3.0〜3.6にす
ることにより安定なリゾチーム水溶液を得ること
が出来ることを見出した。 本発明はこの知見に基礎を置くもので、PH4以
下のリゾチーム水溶液のPHを5−7に上げ、その
前後にもしくはそれと共に繊維質物を加え、析出
する不純物を濾去し、次いで濾液のPHを4以下好
ましくは3−3.6とすることを特徴とする安定な
リゾチーム水溶液の製造法である。 本発明においてはPH4以下のリゾチーム水溶液
を先ずアルカリで中和してそのPHを5−7に上げ
る。 PH4以下のリゾチーム水溶液としてはリゾチー
ム酸塩たとえば塩化リゾチームの水溶液が用いら
れる。 アルカリとしてはたとえば水酸化ナトリウ
ム、、同カリウムなどを便宜に用いうる。 リゾチーム水溶液中の不純物はPH5以上では会
合して析出し易くなる性質があり、その会合は繊
維質物たとえば、パルプ、木綿等を水溶液に混入
することによつて促進される。 水溶液のPH7以下では繊維質物の使用が好まし
いが7を超えるPHことにPH9附近においては繊維
質物を添加しなくても速かに会合が起り不純物が
析出する。 繊維質物はPHを上昇させる前に加えてもよく、
上昇させたのちに加えてもよく、上昇中に加えて
もよい。 繊維質物とリゾチーム水溶液と接触を充分にす
るためには水溶液をゆるくかきまぜるのがよい。 析出した不純物は濾去し、次いで濾液に酸を加
えてPH4以下好ましくは3−3.6に調整する。 PH調整のための酸としてはたとえば、塩酸、硫
酸、リン酸など適宜の酸を用いうるが、リゾチー
ム水溶液の医薬や食品等への前途を考慮した場合
塩酸を用いるのが望ましい。 かくして得られるリゾチーム水溶液はきわめて
安定で、たとえばシロツプ剤その他の用い供する
ことができる。 本発明の効果は次の試験によつても明らかであ
る。 試験処方によるリゾチーム水溶液の検液10mlを
20ml無色アンプルに無菌的に入れ溶封したものを
用い、浮遊物または沈澱物の有無について、48時
間連続振盪後および室温で6ケ月間放置後の経時
変化を観察した。その結果を表1に示す。 (試験処方) 塩化リゾチーム 0.5% エチレンジアミン4酢酸 2ナトリウム 0.005% 10(W/V)% 水酸化ナトリウム溶液 適 量 10(W/V)%塩酸溶液 適 量 塩化ナトリウム 0.9% 滅菌精製水 全量100% (製造法) 塩化リゾチーム500mg、エチレンジアミン4酢
酸2ナトリウム5mgおよび塩化ナトリウム900mg
を滅菌精製水約80mlに溶かし(PH約3.5)、繊維状
にほぐした濾紙くず(パルプ)0.2gを加えたも
のまたは加えないものにつき、さらに10(W/
V)%水酸化ナトリウム溶液を加えてPH5.0およ
び9.0にしたものにつき30分間ゆるくかき混ぜた
後、加圧濾過し、濾液に10(W/V)%塩酸溶液
を加えてPH3.5とした後、蒸留水を加えて全量100
mlとする。これを無菌濾過し無菌操作によりアン
プルに充填し、熔閉する。
The present invention relates to a method for producing a stable aqueous lysozyme solution. Lysozyme is a basic protein consisting of 129 amino acids discovered by Fleming in 1922.
It is an enzyme that is widely distributed in natural products, including human body fluids, and hydrolyzes mucopolysaccharides. It also exhibits pharmacological effects such as anti-inflammatory, hemostatic, antiviral, anti-conjunctivitis, and other anti-ocular inflammation properties, and is therefore important as a pharmaceutical. However, if lysozyme obtained by a known method or an acidic aqueous solution of lysozyme prepared using a lysozyme salt is left for a long period of time, precipitates or suspended matter will occur. Further, lysozyme is commercially available in the form of lysozyme chloride, and its aqueous solution has a pH of 3.0-3.6 and is considered to be stable. However, commercially available lysozyme crystals contain albumin-based impurities or denatured lysozyme, so even if the pH of the aqueous solution is 3.0 to 3.6, they will become precipitates or floats if stored for a long time. Precipitate. As a result of repeated research into the production of a lysozyme aqueous solution that does not have such drawbacks and can withstand long-term storage, the inventors of the present invention have surprisingly conducted extremely simple processing, namely, adjusting the lysozyme aqueous solution to a pH between 5.0 and 11.0 as needed. It was discovered that a stable lysozyme aqueous solution could be obtained by adding pulp and stirring lightly, filtering off a trace amount of precipitated impurities, and then adding acid to adjust the pH to 3.0 to 3.6. The present invention is based on this knowledge, and involves raising the pH of a lysozyme aqueous solution with a pH of 4 or lower to 5-7, adding fibrous materials before, during, or after that, filtering out precipitated impurities, and then lowering the pH of the filtrate. 4 or less, preferably 3-3.6. In the present invention, a lysozyme aqueous solution having a pH of 4 or lower is first neutralized with an alkali to raise its pH to 5-7. As the lysozyme aqueous solution having a pH of 4 or lower, an aqueous solution of a lysozymate salt, such as lysozyme chloride, is used. As the alkali, for example, sodium hydroxide, potassium hydroxide, etc. can be conveniently used. Impurities in an aqueous lysozyme solution tend to aggregate and precipitate at pH 5 or above, and this association is promoted by mixing fibrous materials such as pulp, cotton, etc. into the aqueous solution. When the pH of the aqueous solution is below 7, it is preferable to use a fibrous material, but when the pH exceeds 7, especially around 9, association occurs quickly and impurities precipitate even without the addition of a fibrous material. Fibrous substances may be added before raising the pH,
It may be added after rising or during rising. In order to ensure sufficient contact between the fibrous material and the aqueous lysozyme solution, it is best to stir the aqueous solution gently. The precipitated impurities are removed by filtration, and then acid is added to the filtrate to adjust the pH to 4 or less, preferably 3-3.6. As the acid for pH adjustment, suitable acids such as hydrochloric acid, sulfuric acid, and phosphoric acid can be used, but it is preferable to use hydrochloric acid when considering the potential use of the lysozyme aqueous solution in medicines, foods, etc. The aqueous lysozyme solution thus obtained is extremely stable and can be used, for example, in syrups and other applications. The effects of the present invention are also evident from the following tests. 10 ml of test solution of lysozyme aqueous solution according to the test prescription
The samples were placed in 20 ml colorless ampoules and sealed aseptically, and the presence or absence of floating matter or precipitates was observed over time after continuous shaking for 48 hours and after being left at room temperature for 6 months. The results are shown in Table 1. (Test formulation) Lysozyme chloride 0.5% Disodium ethylenediaminetetraacetic acid 0.005% 10 (W/V)% Sodium hydroxide solution Appropriate amount 10 (W/V)% Hydrochloric acid solution Appropriate amount Sodium chloride 0.9% Sterile purified water Total amount 100% ( Manufacturing method) Lysozyme chloride 500mg, ethylenediaminetetraacetic acid disodium 5mg and sodium chloride 900mg
Dissolved in approximately 80 ml of sterile purified water (PH approximately 3.5), with or without adding 0.2 g of filter paper waste (pulp) loosened into fibers, and an additional 10 (W/
V) After stirring gently for 30 minutes, the pH was adjusted to 5.0 and 9.0 by adding 10% sodium hydroxide solution, filtered under pressure, and the filtrate was adjusted to pH 3.5 by adding 10 (W/V)% hydrochloric acid solution. After that, add distilled water to make the total volume 100.
ml. This is sterile filtered, filled into ampoules by aseptic operation, and melted.

【表】 …沈澱物または浮遊物を生じたもの
+…沈澱物または浮遊物が比較的少ないもの
−…沈澱物または浮遊物を認めないもの
A液とはパルプを用いてPH5.0で不純物除去処
理塩酸でPH3.5としたリゾチーム水溶液。 B液とはパルプを用いずPH5.0で不純物除去処
理後塩酸でPH3.5としたリゾチーム水溶液。 C液とはパルプを用いてPH9.0で不純物除去処
理後塩酸を加えてPH3.5としたリゾチーム水溶
液。 D液とはパルプを用いずPH9.0で不純物除去処
理後塩酸を加えてPH3.5としたリゾチーム水溶
液。 E液とはパルプを用いずPHを3.5で濾過したリ
ゾチーム溶液。 表1に示した如く、リゾチーム水溶液のPHを一
旦5.0以上に上昇させて不純物を除去したものは
顕著に効果を示した。また、PH5.0で不純物を除
去する場合はパルプの使用が有効であつた。 実施例 1 (処方) 塩化リゾチーム 2.2g 塩化ナトリウム 0.5g 10(W/V)%水酸ナトリウム溶液適 量 10(W/V)%塩酸溶液 適 量 蒸留水 全量100ml (製造法) 塩化リゾチーム2.2g、塩化ナトリウム0.5gを
蒸留水70mlに溶かし(PH約3.5)、これに10(W/
V)%水酸化ナトリウム溶液を加えてPH9.0と
し、5分間放置した後、析出した沈澱物を加圧濾
過により濾別し、濾液に10(W/V)%塩酸溶液
を加えてPH3.5とし、これに全量100mlになるよう
に蒸留水を加えて均一とした後、無菌濾過し、注
射用無色アンプル2mlに無菌的に充填熔閉し、筋
注用注射液とする。このものは48時間の連続振盪
および、6ケ月以上の室温放置後も沈澱物または
浮遊物を生成しない。 実施例 2 実施例1の処方について、塩化リゾチーム2.2
g塩化ナトリウム0.5gを蒸留水70ml溶かし(PH
約3.5)、これに繊維状にほぐした濾紙くず(パル
プ)0.2gを加え、さらにこれに10(W/V)%
水酸化ナトリウム溶液を加えてPH7とし、30分間
ゆるくかき混ぜた後、加圧濾過し、濾液に10
(W/V)塩酸溶液を加えてPH3.5とし、蒸留水を
加えて全量100mlとする。以下実施例1と同様に
操作した。製品の安定性も同様であつた。 実施例 3 (処方) 塩化リゾチーム 0.55g D−ソルビトール(70%液) 75ml パラオキシ安息香酸メチル 28mg パラオキシ安息香酸プロピル 12mg 10(W/V)% 水酸化ナトリウム液 適 量 10(W/V)%塩酸溶液 適 量 香 料 微 量 精製水 全量100ml (製造法) 塩化リゾチーム0.55gを精製水10mlに溶かし
(PH約3.3)、これに繊維状にほぐした濾紙くず0.2
gおよび10(W/V)%水酸化ナトリウム液を加
えてPH5.0とし、30分間ゆるくかき混ぜた後、加
圧濾過で濾過し、濾液に10(W/V)%塩酸溶液
を加えてPH3.3とする(これをA液とする)。一
方、D−ソルビトール液(70%)75mlにパラオキ
シ安息香酸メチル28mgおよびパラオキシ安息香酸
プロピル12mgを加えて加然して溶かし、以後エチ
レンジアミン4酢酸カルシウム2ナトリウム0.01
gを加えて溶かし、これにA液を加え、さらに微
量の香料および精製水を加えて全量100mlとし、
濾過して、ポリプロピレン容器に充填し、シロツ
プ剤として使用する。 安定性は実施例1と同様であつた。 実施例 4 (処方) 実施例3と同じ。 (製造法) 塩化リゾチーム0.55gを精製水10mlに溶かし
(PH約3.3)、これに10(W/V)%水酸化ナトリ
ウム液を加えて、PH8.8とし、5分間放置した
後、析出した沈澱物を加圧濾過し、濾液に10
(W/V)%塩酸溶液を加えてPH3.3とする。 以下実施例3と同様に操作する。 安定性については実施例1と同様であつた。
[Table] ...Those with precipitates or suspended matter +...Those with relatively little amount of precipitates or suspended matter -...Those where no precipitates or suspended matter are observed Liquid A is pulp that removes impurities at PH5.0. Lysozyme aqueous solution adjusted to pH3.5 with treated hydrochloric acid. Solution B is an aqueous lysozyme solution that does not use pulp and is treated to remove impurities at pH 5.0 and then adjusted to pH 3.5 with hydrochloric acid. Solution C is an aqueous lysozyme solution that uses pulp to remove impurities at pH 9.0 and then adjusts the pH to 3.5 by adding hydrochloric acid. Solution D is an aqueous lysozyme solution that does not use pulp and is treated to remove impurities at pH 9.0 and then adjusted to pH 3.5 by adding hydrochloric acid. Solution E is a lysozyme solution that is filtered at a pH of 3.5 without using pulp. As shown in Table 1, the lysozyme aqueous solution in which the pH was once raised to 5.0 or higher to remove impurities was significantly effective. In addition, the use of pulp was effective when removing impurities at pH 5.0. Example 1 (Formulation) Lysozyme chloride 2.2g Sodium chloride 0.5g 10(W/V)% sodium hydroxide solution Appropriate amount 10(W/V)% Hydrochloric acid solution Appropriate amount Distilled water Total volume 100ml (Production method) Lysozyme chloride 2.2g , dissolve 0.5 g of sodium chloride in 70 ml of distilled water (PH approx. 3.5) and add 10 (W/
V) % sodium hydroxide solution was added to adjust the pH to 9.0, and after leaving it for 5 minutes, the precipitate was separated by pressure filtration, and a 10 (W/V) % hydrochloric acid solution was added to the filtrate to adjust the pH to 3. 5, add distilled water to make it homogeneous to a total volume of 100 ml, filter aseptically, and fill and seal aseptically into a colorless ampoule for injection of 2 ml to obtain an intramuscular injection solution. This product does not produce precipitates or suspended matter even after 48 hours of continuous shaking and standing at room temperature for more than 6 months. Example 2 For the formulation of Example 1, lysozyme chloride 2.2
Dissolve 0.5g of sodium chloride in 70ml of distilled water (PH
Approximately 3.5), add 0.2 g of filter paper waste (pulp) loosened into fibers, and add 10 (W/V)% to this.
Add sodium hydroxide solution to adjust the pH to 7, stir gently for 30 minutes, filter under pressure, and add 10% to the filtrate.
(W/V) Add hydrochloric acid solution to adjust the pH to 3.5, and add distilled water to make a total volume of 100 ml. The following operations were carried out in the same manner as in Example 1. The stability of the products was also similar. Example 3 (Formulation) Lysozyme chloride 0.55g D-sorbitol (70% liquid) 75ml Methyl paraoxybenzoate 28mg Propyl paraoxybenzoate 12mg 10(W/V)% sodium hydroxide solution Appropriate amount 10(W/V)% hydrochloric acid Solution Appropriate amount Flavor Small amount Purified water Total volume 100ml (Production method) Dissolve 0.55g of lysozyme chloride in 10ml of purified water (PH approximately 3.3), add 0.2g of filter paper scraps loosened into fibers.
g and 10 (W/V)% sodium hydroxide solution to adjust the pH to 5.0, stir gently for 30 minutes, filter by pressure filtration, and add 10 (W/V)% hydrochloric acid solution to the filtrate to adjust the pH to 3. .3 (this is called liquid A). On the other hand, 28 mg of methyl paraoxybenzoate and 12 mg of propyl paraoxybenzoate were added to 75 ml of D-sorbitol solution (70%) and dissolved, followed by 0.01 ml of calcium disodium ethylenediaminetetraacetate.
g and dissolve, add liquid A to this, add a small amount of fragrance and purified water to make a total volume of 100 ml,
Filter and fill into polypropylene containers for use as syrup. Stability was similar to Example 1. Example 4 (Formulation) Same as Example 3. (Manufacturing method) 0.55 g of lysozyme chloride was dissolved in 10 ml of purified water (PH approx. 3.3), 10 (W/V)% sodium hydroxide solution was added to the solution to adjust the pH to 8.8, and after standing for 5 minutes, the solution precipitated. Filter the precipitate under pressure, and add 10% to the filtrate.
Add (W/V)% hydrochloric acid solution to adjust the pH to 3.3. The following operation is carried out in the same manner as in Example 3. The stability was the same as in Example 1.

Claims (1)

【特許請求の範囲】[Claims] 1 PH4以下のリゾチーム水溶液のPHを5−7に
上げ、その前後にもしくはそれと共に繊維質物を
加え、析出する不純物を濾去し、次いで濾液のPH
を4以下、好ましくは3−3.6とすることを特徴
とする安定なリゾチーム水溶液の製造法。
1 Raise the pH of the lysozyme aqueous solution with a pH of 4 or less to 5-7, add fibrous material before, during, or after that, filter out precipitated impurities, and then lower the pH of the filtrate.
4 or less, preferably 3-3.6.
JP14440078A 1978-11-21 1978-11-21 Preparation of stable aqueous solution of lysozyme Granted JPS5571490A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP14440078A JPS5571490A (en) 1978-11-21 1978-11-21 Preparation of stable aqueous solution of lysozyme

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14440078A JPS5571490A (en) 1978-11-21 1978-11-21 Preparation of stable aqueous solution of lysozyme

Publications (2)

Publication Number Publication Date
JPS5571490A JPS5571490A (en) 1980-05-29
JPS6261313B2 true JPS6261313B2 (en) 1987-12-21

Family

ID=15361273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14440078A Granted JPS5571490A (en) 1978-11-21 1978-11-21 Preparation of stable aqueous solution of lysozyme

Country Status (1)

Country Link
JP (1) JPS5571490A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314816A (en) * 1990-01-08 1994-05-24 Nika Health Products Ltd. Method of preparing lysozyme dimers
US5989880A (en) 1990-01-08 1999-11-23 Nika Health Products Ltd. Method of preparing lysozyme dimers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5516413B2 (en) * 1973-08-10 1980-05-01

Also Published As

Publication number Publication date
JPS5571490A (en) 1980-05-29

Similar Documents

Publication Publication Date Title
US3396081A (en) Hyaluronic acid preparation and method of producing same
SU786854A3 (en) Method of producing protein serum-based preparate
DE69004101T2 (en) METHOD FOR CRYSTALLIZING ENZYMS.
JPS5843914A (en) Intravenously injectable immunogloblin
EP0784632A1 (en) Process for extracting high-purity von willebrand factor
DE3787913T2 (en) Means and methods for removing nucleic acids and / or endotoxin.
DE3061547D1 (en) Process of preparation of an intravenous immunoglobulin solution, containing concentrated igm
US3329572A (en) Process for treating animal tissues and product
FR2583982A1 (en) MEDICINAL PRODUCT OBTAINED FROM THYMUS AND METHOD OF OBTAINING THE SAME
JPS6261313B2 (en)
US4379086A (en) Method of preparing immunoglobulin suitable for intravenous administration using PEG
DE69727736T2 (en) Process for activating prothrombin to thrombin
CN1087610C (en) Lentinus edodes polysaccharide injecta and its preparation
JPS58148824A (en) Preparation of fibrinolytic active substance
ES2263190T3 (en) PROCEDURE FOR THE PRODUCTION OF A PREPARED CONTAINING Hyaluronidase.
JPH03501563A (en) Method for preparing ribonucleotide mixtures
US2446974A (en) Synthesis of a penicillin-protein reaction product
CN104593345A (en) Method for separation and purification of trypsin and pharmaceutical composition containing trypsin
SU615933A1 (en) Method of lyophilic drying of immunoglobulins
AT367297B (en) METHOD FOR PRODUCING A SERUM PROTEIN PR [PARATE
CN1126076A (en) Pearl liquid for improving eyesight
KR20110056346A (en) Manufacturing method of high purity medical hyaluronic acid
SU467536A1 (en) The method of obtaining serum albumin
CH629819A5 (en) Process for the isolation of albumin from human blood plasma
RU2052265C1 (en) Method of preparing hyaluronic acid preparation for use in ophthalmology